Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
Status:
Not yet recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and
efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation
positive non-small cell lung cancer.